血清可溶性血管内皮生长因子受体-1和胎盘生长因子鉴别慢性肾病和子痫前期的临床应用  

Clinical application of placental growth factor and soluble Fms-like tyrosine kinase-1 in differentiating between chronic kidney disease and preeclampsia

作　　者：刘进[1] 钟华[2] 

机构地区：[1]泸州医学院附属医院肾内科,四川泸州646000 [2]四川大学华西医院,四川成都610041

出　　处：《中国现代医学杂志》2014年第29期46-49,共4页China Journal of Modern Medicine

摘　　要：目的试验孕妇血清可溶性血管内皮生长因子受体-1(sFlt-1)和胎盘生长因子(PLGF)两子痫前期标志物是否能用于鉴别孕妇妊娠期慢性肾病(CKD)和子痫前期(PE)。方法在孕晚期用酶联免疫吸附试验(ELISA)检测62例PE、44例妊娠期CKD和67例健康孕妇血清sFlt-1和PLGF水平。结果 PE患者血清sFlt-1水平明显高于CKD孕妇和健康孕妇。PE患者血清PLGF水平明显低于CKD孕妇和健康孕妇。PE患者sFlt-1/PLGF比值(平均值427.4)明显高于CKD孕妇(平均值15.5)和健康孕妇(平均值18.9)。但在CKD和健康孕妇间差异无统计学意义。结论孕妇血清sFlt-1和PLGF水平,特别是其比值可鉴别孕妇子痫前期和CKD,是一种快速的非侵入性方法。【Objective】 To study whether maternal serum levels of placental growth factor（PLGF） and soluble Fms-like tyrosine kinase-1（sFlt-1）, markers of preeclampsia（PE）, could be used to discriminate between PE and chronic kidney disease（CKD） during pregnancy. 【Methods】 Serum levels of PLGF and sFlt-1 in 62 patients with PE, 44 patients with CKD during pregnancy, and 67 healthy pregnant women were determined by enzyme-linked immunosorbent assay（ELISA） during the third trimester. 【Results】 In PE, sFlt-1 levels were significantly increased in comparison with that in CKD and in the control women. Serum levels of PLGF in PE were significantly decreased relative to both controls and patients with CKD. The sFlt-1 to PLGF ratio was significantly increased in PE（mean 427.4） compared with controls（mean 18.9） and CKD（mean 15.5）. No differences were found between controls and patients with CKD. 【Conclusion】 Maternal serum levels of sFlt-1 and PLGF and in particular their ratio could discriminate between preeclampsia and CKD during pregnancy and may be a rapid noninvasive method.

关 键 词：慢性肾病 内皮 肾小球病 高血压 

分 类 号：R692[医药卫生—泌尿科学]